Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Amortizatization of Intangibles: 2023-2025

Historic Amortizatization of Intangibles for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $357,000.

  • Artiva Biotherapeutics' Amortizatization of Intangibles fell 45.83% to $357,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 66.20%. This contributed to the annual value of $2.3 million for FY2024, which is 413.60% up from last year.
  • According to the latest figures from Q3 2025, Artiva Biotherapeutics' Amortizatization of Intangibles is $357,000, which was down 29.86% from $509,000 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Amortizatization of Intangibles ranged from a high of $1.0 million in Q4 2024 and a low of $159,000 during Q3 2023.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $368,000 (2024), whereas its average is $485,889.
  • In the last 5 years, Artiva Biotherapeutics' Amortizatization of Intangibles surged by 314.47% in 2024 and then plummeted by 45.83% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Amortizatization of Intangibles (Quarterly) stood at $283,000 in 2023, then skyrocketed by 268.20% to $1.0 million in 2024, then crashed by 45.83% to $357,000 in 2025.
  • Its last three reported values are $357,000 in Q3 2025, $509,000 for Q2 2025, and $723,000 during Q1 2025.